1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.
-
Upload
eustace-lang -
Category
Documents
-
view
220 -
download
0
Transcript of 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.
![Page 1: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/1.jpg)
1
Complying with FDA/OIG Rules
Wayne L. Pines August 24, 2006
![Page 2: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/2.jpg)
2
Wayne PinesConsultant to pharma/devices industries on advertising/promotion issues, crisis controlFormer Associate Commissioner for Public Affairs, FDAAuthor/editor, FDA Advertising and Promotion Manual, 10 others books
![Page 3: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/3.jpg)
3
Traditional Marketing Regulation
FDA enforcement of advertising/promotion rules
Dates to 1960’sPenalties are warning or untitled lettersTend to focus on print materials
Not dinner meetings, CME, non-traditional promotion
Limited impact of penalties
![Page 4: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/4.jpg)
4
The Industry’s New 800-Pound Gorilla(s)
Fraud and abuse cases filed by OIG/DOJHas cost industry $3 billion plusMuch more to comePlus:
PhRMA rulesOIG rulesState restrictions on gifts etc.State AGsLiability cases
![Page 5: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/5.jpg)
5
New DevelopmentPsychiatrist arrested for promoting Xyrem off-label at dinner meetingsShows seriousness of government against off-label promotion
![Page 6: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/6.jpg)
6
Bottom LinesPharma companies facing a new environment in terms of promoting their productsHCPs will have less “off-label” information available, even when medically justifiedWill affect promotion, prescribing, reimbursement, general information flow
![Page 7: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/7.jpg)
7
I. Inspector General of HHS (DOJ)II. ACCMEIII. PhRMAIV. AMAV. FDA
Big Five Regulators of Pharma Promotion
![Page 8: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/8.jpg)
8
I. OIG RulesFalse Claims Act
Originally passed in 1863Amended in 1986Government using it as weapon against drug/device companies
Anti-Kickback Statute
![Page 9: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/9.jpg)
9
Underlying ConcernLaw prohibits payments by government when fraud is involved in the saleGovernment now pays for drugs under Medicare, Medicaid, VA, Defense Department etc.
![Page 10: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/10.jpg)
10
OIG Legal TheoryGovernment theory:
When a company promotes off-label, andThen a physician prescribes the product for the off-label use, andThen the government pays for the off-label use under one of its programs –Then that is fraud against the government
![Page 11: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/11.jpg)
11
How Cases DevelopWhistleblowers bring against their own companies (can bring against anyone)
“Qui tam”
Whistleblowers get 15-30% of the settlement fineSignificant inducement for internal whistleblowers, disgruntled employeesRecent cases have changed HR practices in drug/device companies
![Page 12: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/12.jpg)
12
The Future For the Industry
Government now investigating more than 150 casesThis is why companies are so cautious
![Page 13: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/13.jpg)
13
II. ACCMESets rules on independence of Continuing Medical Education programsFollow FDA, OIG guidance and PhRMA and AMA guidelines
![Page 14: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/14.jpg)
14
III. PhRMA CodesCode created by PhRMA in 2002, but adopted by OIG, CaliforniaDTC Principles effective Jan. 1, 2006
![Page 15: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/15.jpg)
15
PhRMA CodeRules on gift-giving, grants, use of consultants, general relationship between pharma companies and HCPsEffective 2002Has become standard in industryReflected in OIG rules, CA statute
![Page 16: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/16.jpg)
16
PhRMA CodeOccasional modest meals may still be offered, so long as educational venue. No spouses. No dine ‘n dash. CME: Companies can sponsor medical conferences. Cannot control content or venue. Cannot pay doc’s expenses to attend.
![Page 17: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/17.jpg)
17
PhRMA Code - Consultants
Consultants can be paid for their time
Services must be legitimateProhibits “token” consulting arrangements
Continued
![Page 18: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/18.jpg)
18
Consultant AgreementsSix factors for a bona fide arrangement:
Written contractLegitimate need for services, identified in advanceSelection criteria related to service Number of consultants should not be more than necessary to achieve purposeServices actually provided and documentedVenue and circumstances conducive to services
Social events “clearly subordinated”No support for consultant spouses
![Page 19: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/19.jpg)
19
PhRMA Code – Speakers Bureau
Speaker training OK, so long as speakers will actually be used and they meet criteria for consultants
Reasonable payments Speakers receive “extensive training” on company’s products and FDA requirements
Training will result in participants providing a valuable service to companyParticipants meet same criteria applicable to consultantsNumber of trainees cannot significantly exceed number the company uses
![Page 20: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/20.jpg)
20
PhRMA Code - GrantsCompanies can support scholarships/educational grants
Selection must be made by independent/academic institutionsProcess is independent of marketing
![Page 21: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/21.jpg)
21
PhRMA Code - GiftsGifts
Prohibited for personal benefit Appropriate gifts ($100 or less) primarily benefiting patients are OK on occasional basis, as are gifts of “nominal” value (e.g., pens, notepads)
MealsModest meals during informational presentation are permitted in appropriate venue; spouses prohibited
Entertainment and recreational eventsGenerally prohibitedException: In context of meetings with parties providing bona fide services to the company)
Samples: Permitted for patient use; prohibited for personal/family use
![Page 22: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/22.jpg)
22
PhRMA DTC Principles
Professional education should precede DTCNo more TV “reminder ads”Ads should be appropriate for audienceSubmission of DTC ads to FDA for advance review
![Page 23: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/23.jpg)
23
IV. AMA Guidelines on Gifts
Any gift should “primarily” entail a benefit to patient, and not be of “substantial value” ($100)
Texts, modest meals are OK if they serve educational purposePens, diaries are OK if related to work
Gifts to support medical meetings OK BUT
Cannot pay for travel, lodging, personal expenses, physician’s timeModest hospitality OK
![Page 24: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/24.jpg)
24
AMA GuidelinesFaculty at conferences and consultants may get honoraria and travel/lodging reimbursementNo gifts with “strings attached”Financial support for conferences should be disclosed
![Page 25: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/25.jpg)
25
V. FDA RulesPromotion must
Be within labelingInclude fair balance of benefits/risksNot be false and/or misleading
![Page 26: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/26.jpg)
26
FDA’s ExpectationsCompliance with FDA’s view of the rulesStandard operating procedures
Internal review process
Company-wide control by managementSales force
Distribute only approved materialsRefer off-label questions to Medical Affairs
![Page 27: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/27.jpg)
27
Off-label DisseminationFDA prohibits promotion of off-label usesWashington Legal Foundation litigation:
Dealt only with peer-reviewed articles to health professionals
Companies can disseminate peer-reviewed articles and texts under two processes:
Follow process in FDAMA 401Do it without FDA approval
FDA will bring action if material is “false and misleading” or if part of larger of-label campaign
![Page 28: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/28.jpg)
28
Investigational Products/Uses
Regulation 312.7:“A sponsor…shall not represent in a promotional context that an investigational new drug is safe or effective…“This provision is not intended to restrict the full exchange of scientific information… including (in) the lay media…“Rather, its intent is to restrict promotional claims of safety or effectiveness…and commercialization of a new drug before it is approved.”
![Page 29: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/29.jpg)
29
Enforcement 200612 DDMAC enforcement letters thus far in 2006Focus on:
Lack of fair balanceRisk minimizationUnwarranted claims
DDMAC on same track as 2004-5But, no DTC letters
![Page 30: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/30.jpg)
30
Tips for Overall Compliance
Every company should have culture of compliance
Too much at stake if there are lapsesQui tam provides strong incentive for whistleblowers
![Page 31: 1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062305/5697bff61a28abf838cbe4d5/html5/thumbnails/31.jpg)
31
Tips for Compliance1. Every company should have an OIG-type compliance program:
• Written policies & procedures• Designating a compliance officer• Effective training and education• Effective means of communication• Internal monitoring & auditing• Well-publicized disciplinary guidelines• Prompt detection of problems &
corrective action